Register Now
Why register?
 The leading web portal for pharmacy resources, news, education and careers October 23, 2017
Pharmacy Choice - Pharmaceutical News - FDA Drug Approvals on the Rise in 2017: Today's Research Reports on Sarepta Therapeutics and TG Therapeutics - October 23, 2017

Pharmacy News Article

 4/18/17 - FDA Drug Approvals on the Rise in 2017: Today's Research Reports on Sarepta Therapeutics and TG Therapeutics

NEW YORK, NY / ACCESSWIRE / April 18, 2017 /The volatile Biotech Industry has continued to be home to some of the largest gainers on the market in 2017. President Trump's pledge for a faster FDA approval process has already paid dividends for the industry as the FDA has already approved 13 new drugs in 2017, compared to just 22 new drug approvals in 2016. The iShares NASDAQ Biotechnology Index ETF and SPDR S&P Biotech ETF have posted gains of 9.5 percent and 16.25 percent, respectively, year-to-date.

RDI Initiates Coverage on:

Sarepta Therapeutics Inc.

TG Therapeutics Inc.

Sarepta Therapeutics' shares gained 2.84 percent to close at $30.78 a share on Monday. The stock traded between $29.84 and $31.35 on volume of 1.49 million shares traded. The Company is primarily focused on rapidly advancing the development of its potentially disease-modifying Duchenne muscular dystrophy (DMD) drug candidates. Sarepta is scheduled to release results for the first quarter of 2017 after market close on Thursday, April 27th. The company reported a loss of $1.62 per share on revenues of $5.42 million in the fourth quarter of 2016. Shares of Sarepta Therapeutics have gained approximately 12.21 percent year-to-date.

Access RDI's Sarepta Therapeutics Research Report at:

TG Therapeutics' shares increased 6.06 percent to close at $10.50 a share on Monday. The stock traded between $9.85 and $10.69 on volume of 1.39 million shares traded. Currently, the company is developing two therapies targeting hematological malignancies and autoimmune diseases. On April 5th, TG Therapeutics presented preclinical data on the company's novel fully human anti-PD-L1 monoclonal antibody at the American Association for Cancer Research (AACR) annual meeting in Washington D.C. Shares of TG Therapeutics have gained approximately 125.81 percent year-to-date.

Michael S. Weiss, the Company's Executive Chairman and CEO stated, "The team has worked hard to develop a high quality anti-PD-L1 antibody which we believe is the cornerstone of any proprietary immune-oncology (I/O) strategy. While anti-PD-1/PD-L1 therapy has been broadly explored in solid tumors, we are still in the very early days of understanding their utility and best applications in B-cell malignancies."

Access RDI's TG Therapeutics Research Report at:

Our Actionable Research on Sarepta Therapeutics Inc. (NASDAQ: SRPT) and TG Therapeutics Inc. (NASDAQ: TGTX) can be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of and reviewed by Nadia Noorani, CFA charter holder. is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at


For any questions, inquiries, or comments reach out to us directly at:


Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011


CFA and Chartered Financial Analyst are registered trademarks owned by CFA Institute.

Copyright © 2017 accesswire. All Rights Reserved.

Pharmacy News Index
  Drug Delivery Systems
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry


Last Chance
Oct 23: Vitamin D Primer for Pharmacy Professionals
Last Chance
Oct 24: Metabolic Syndrome: The Heart of Any Wellness Practice
Oct 25: Dispensing Controlled Substances in Today’s Pharmacy
Oct 26: Management of Schizophrenia & Acute Agitation
Oct 27: Influenza 2017-2018: An Update on Prevention and Treatment
Click for entire Webinar Calendar

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...

Nursing Jobs
Are you a nurse looking for a job?

Check out the Nursing Job Source.

Your number one choice for nursing jobs.

Websites »
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement